Quick answer
Keith Dunleavy's net worth is $4.6 billion, according to the Forbes 400 list published in September 2026, where the Inovalon founder debuted at rank #375. Forbes' real-time tracker nudged the figure to about $4.67 billion in early October 2026 — a sign that the rocket fuel behind his 2026 debut is still burning. Dunleavy is one of 34 newcomers to this year's Forbes 400, a class that included SpaceX-stake windfalls for several new billionaires after the rocket company's blockbuster June 2026 IPO.
The story of the fortune has two acts. Act one is Inovalon, the cloud-based healthcare data and analytics company Dunleavy conceived during his internal medicine residency at Johns Hopkins, ran as CEO for 26 years, took public on the Nasdaq in 2015, and sold to a Nordic Capital-led consortium for $7.3 billion in 2021. Act two is Apandion, his self-funded investment firm, which Forbes says backed SpaceX before its IPO — the stake that pushed him onto the Forbes 400. For the full founding story, see how Keith Dunleavy made his money.
The September 2026 Forbes 400 debut
Forbes publishes the Forbes 400 every September, and the 2026 edition raised the bar: the minimum net worth for inclusion climbed to $4.4 billion, knocking three people off the list entirely. Dunleavy cleared it with room to spare at $4.6 billion. Healthcare trade press picked up the debut immediately — Becker's flagged him on September 15, 2026 as one of four physician-billionaires on the list, alongside Thomas Frist Jr., Patrick Soon-Shiong, and August Troendle.
What made 2026 his year was not Inovalon, but the rocket company. Coverage of the newcomers noted that Dunleavy "made the cut after his self-funded investment firm, Apandion, became a pre-IPO backer of SpaceX." His Forbes profile lists Space Exploration Technologies Corp. (SPCX-US) among his financial assets — the public-market residue of a bet placed well before SpaceX's IPO. It is a familiar pattern on the 2026 list: founder-led investment firms capturing pre-IPO upside in the year's defining listing.
| Tracker | Figure | As of |
|---|---|---|
| Forbes 400 (annual list) | $4.6B (#375) | September 2026 — debut |
| Forbes real-time tracking | ~$4.67B | Early October 2026 |
| Forbes 400 cutoff (minimum) | $4.4B | 2026 list |
How the $4.6B fortune breaks down
Forbes attributes Dunleavy's wealth to health IT and investments, and the profile gives enough to sketch the structure. The anchor is his roughly 15% stake in Inovalon — a private company today, which is why his Forbes figure does not swing with a stock price the way public-company billionaires' fortunes do. Then comes the disclosed SpaceX position via Apandion, and a portfolio of other founder-led tech investments that Forbes does not itemize.
| Asset | Share of fortune | Notes |
|---|---|---|
| Inovalon stake (~15%) | Majority | Retained through the 2021 take-private; Dunleavy sits on the board |
| SpaceX (via Apandion) | Disclosed, size not itemized | Pre-IPO backer; listed on his Forbes profile as SPCX-US |
| Other Apandion investments | Undisclosed | Self-funded firm focused on founder-led tech firms; includes Shield AI |
| Cash & other assets | Undisclosed | Proceeds from partial cash-outs; salary income was modest |
One structural point matters: because Inovalon is private and his other holdings are opaque, Forbes' number is an estimate built on the company's performance and the SpaceX stake — not a live mark-to-market. That is also why the figure moved from $4.6 billion to about $4.67 billion within weeks: SpaceX's post-IPO price moves the needle while Inovalon's value is re-estimated periodically.
The $7.3 billion sale that built the base
The single most important transaction of Dunleavy's career was announced on August 19, 2021: Inovalon agreed to be acquired by an equity consortium led by Nordic Capital, joined by Insight Partners as lead co-investor, 22C Capital, and — unusually — Dunleavy himself, alongside certain Class B stockholders, in an all-cash deal with an enterprise value of approximately $7.3 billion. Shareholders received $41.00 per share in cash, a 25.3% premium over the last unaffected closing price.
Dunleavy was both seller and buyer. Merger disclosures said he owned and controlled about 64% of Inovalon's outstanding stock ahead of the deal, and he rolled much of that equity into the private company instead of taking all cash. The special committee of independent directors approved the transaction; Dunleavy recused himself from the board vote. Inovalon has run as a private company since, from its Bowie, Maryland headquarters, where Dunleavy stayed on as CEO through the transformation to a pure-play cloud SaaS and data platform provider.
From residency idea to Nasdaq IPO
Dunleavy's origin story is a doctor's version of the garage-startup myth. He completed an internal medicine residency at The Johns Hopkins Hospital in Baltimore — after earning his MD from Harvard Medical School and a bachelor's in biology modified with engineering, with high honors, from Dartmouth College ('91) — and conceived Inovalon's core idea during that residency: using cloud software and data analytics to improve clinical outcomes and the economics of healthcare. He became Inovalon's CEO in 1998 and its chairman in 2006.
The numbers grew relentlessly. He led more than ten acquisitions and divestitures, oversaw the company's 2015 IPO on the Nasdaq under the ticker INOV, and built the Inovalon ONE Platform — which by September 2026 powered the data of more than 99 billion medical, pharmacy, and lab events across 461 million unique lives for over 50,000 active, licensed customers, from health plans and hospitals to pharmacies and life-sciences researchers. Along the way he was inducted into Dartmouth's Entrepreneurs Hall of Fame, and in 2015 received the EY Entrepreneur of the Year award in the growth category.
Apandion, SpaceX, and the pre-IPO bet
After the 2021 sale left him with enormous liquidity, Dunleavy did what many founder-billionaires do — but with a twist. He founded Apandion, an investment firm backed solely by his own funds, focused on founder-led technology companies. Forbes names two of its investments: SpaceX and Shield AI, the San Diego-based defense-tech company building AI pilots for aircraft.
The SpaceX position is the one that matters for his 2026 debut. Apandion backed SpaceX before its IPO, and the June 2026 listing — described as a blockbuster — crystallized the value of that stake. It is a pattern worth noting: Dunleavy spent 26 years building one company, then used a self-funded vehicle to piggyback on the decade's most watched private-company listing. He is, in effect, an operator who became an allocator, and the Forbes 400 debut is the receipt. For more on the portfolio, see Keith Dunleavy's companies.
Personal life, foundation, and a private style
Dunleavy is one of the most low-profile billionaires on the Forbes 400 — there are no widely published photographs of him, and he gives few interviews. What is on the record: he is married with four children, lives in Annapolis, Maryland, and in 2020 he and his wife created the Dunleavy Foundation, which supports education, social entrepreneurship, and U.S. service members and veterans.
The Dartmouth profile adds texture to the biography. As a young child, Dunleavy suffered serious injuries in an accident but recovered. Years later, his older brother died in an ice-climbing accident. He went on to medical school, then bet his twenties and thirties on a data-and-analytics company with what Dartmouth called "the audacious goal of leveraging data and analytics to improve patient outcomes." Colleagues from that era remember him as the first one in the office in the morning and the last to leave at night.
What could move the number next
Three variables will decide where Dunleavy's fortune goes from here. First, Inovalon's private valuation — the company keeps growing its data assets (99 billion medical events and counting) and its SaaS transformation; any secondary transaction or future event would reprice his 15% stake. Second, SpaceX's public price, which now moves the needle daily on the disclosed portion of his wealth. Third, Apandion's next bets — Shield AI and the rest of the founder-led portfolio are still private, and their markups or markdowns will flow into Forbes' estimate with a lag.
One thing will not move it much: salary. As Inovalon's founder-CEO, Dunleavy deliberately kept his own pay tiny — a $205,000 base salary with no bonus and no equity grants by choice, per the company's proxy disclosures. His wealth was always the equity. That is why the $7.3 billion sale, not any paycheck, is the foundation of the $4.6 billion fortune. For the details, see Keith Dunleavy's salary — and how it compares to his fellow physician-billionaire in Dunleavy vs. August Troendle.
Frequently asked questions
What is Keith Dunleavy's net worth in 2026?
Keith Dunleavy's net worth is $4.6 billion, according to the Forbes 400 list published in September 2026, where he debuted at rank #375. A Forbes real-time tracking put the figure at about $4.67 billion in early October 2026, after his self-funded investment firm Apandion was revealed as a pre-IPO backer of SpaceX.
Why did Keith Dunleavy debut on the Forbes 400 in 2026?
Dunleavy made the 2026 Forbes 400 as one of 34 newcomers after Apandion, his self-funded investment firm, was disclosed as a pre-IPO backer of SpaceX ahead of the rocket company's blockbuster June 2026 IPO. He built his core wealth from Inovalon, the health-data company he founded in 1998, took public in 2015, and sold for $7.3 billion in 2021.
What percentage of Inovalon does Keith Dunleavy own?
Forbes says Dunleavy still owns roughly a 15% stake in Inovalon and serves on its board of directors. Ahead of the 2021 take-private, merger disclosures said he owned and controlled about 64% of Inovalon's outstanding stock; he rolled a large portion of that equity into the private company rather than cashing out fully.
How did Keith Dunleavy make his money?
Dunleavy conceived Inovalon during his internal medicine residency at Johns Hopkins, became its CEO in 1998, and ran it for 26 years — through a 2015 Nasdaq IPO, a $7.3 billion sale to a Nordic Capital-led consortium in 2021, and its transformation into a pure cloud SaaS platform. He retired as CEO on March 1, 2025, and also founded Apandion, the investment firm behind his pre-IPO SpaceX stake.
How does Keith Dunleavy's net worth compare to other healthcare billionaires?
At $4.6 billion (#375), Dunleavy ranks just above fellow physician-founder August Troendle ($4.4 billion, #396), the Medpace founder who also debuted on the 2026 list. Both are well below Patrick Soon-Shiong ($10.3 billion, #151) and Thomas Frist Jr. ($33.6 billion, #32), the two richest doctors on the Forbes 400.
Is Keith Dunleavy married?
Yes. Forbes lists Dunleavy's marital status as married, and he has four children. In 2020 he and his wife created the Dunleavy Foundation, which supports education, social entrepreneurship, and U.S. service members and veterans. True to his low profile, no public record names his wife.
How old is Keith Dunleavy in 2026?
Keith Dunleavy was born on June 25, 1969, and is 57 years old in 2026. He graduated from Dartmouth College in 1991, earned his MD from Harvard Medical School, and completed an internal medicine residency at Johns Hopkins Hospital.
Where does Keith Dunleavy live?
Forbes lists Dunleavy's residence as Annapolis, Maryland. He grew up in the region, built Inovalon at its Bowie, Maryland headquarters — about 30 miles west of Annapolis — and has kept his roots in the Chesapeake Bay area throughout his career.